256 related articles for article (PubMed ID: 33475293)
1. Targeted Treatment of Triple-Negative Breast Cancer.
Young JA; Tan AR
Cancer J; 2021 Jan-Feb 01; 27(1):50-58. PubMed ID: 33475293
[TBL] [Abstract][Full Text] [Related]
2. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
Bardia A; Mayer IA; Vahdat LT; Tolaney SM; Isakoff SJ; Diamond JR; O'Shaughnessy J; Moroose RL; Santin AD; Abramson VG; Shah NC; Rugo HS; Goldenberg DM; Sweidan AM; Iannone R; Washkowitz S; Sharkey RM; Wegener WA; Kalinsky K
N Engl J Med; 2019 Feb; 380(8):741-751. PubMed ID: 30786188
[TBL] [Abstract][Full Text] [Related]
3. Case report of sacituzumab govitecan-hziy-induced neutropenia in a patient with metastatic triple-negative breast cancer and a uridine diphosphate glucuronosyltransferase family 1 member A1 poor metabolizer genotype.
Baek G; Jung L; Duong A; Gralow J
J Oncol Pharm Pract; 2022 Apr; 28(3):710-716. PubMed ID: 34761708
[TBL] [Abstract][Full Text] [Related]
4. Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer.
Seligson JM; Patron AM; Berger MJ; Harvey RD; Seligson ND
Ann Pharmacother; 2021 Jul; 55(7):921-931. PubMed ID: 33070624
[TBL] [Abstract][Full Text] [Related]
5. Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors.
Fenn KM; Kalinsky K
Drugs Today (Barc); 2019 Sep; 55(9):575-585. PubMed ID: 31584574
[TBL] [Abstract][Full Text] [Related]
6. Sacituzumab Govitecan: First Approval.
Syed YY
Drugs; 2020 Jul; 80(10):1019-1025. PubMed ID: 32529410
[TBL] [Abstract][Full Text] [Related]
7. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
Bardia A; Hurvitz SA; Tolaney SM; Loirat D; Punie K; Oliveira M; Brufsky A; Sardesai SD; Kalinsky K; Zelnak AB; Weaver R; Traina T; Dalenc F; Aftimos P; Lynce F; Diab S; Cortés J; O'Shaughnessy J; Diéras V; Ferrario C; Schmid P; Carey LA; Gianni L; Piccart MJ; Loibl S; Goldenberg DM; Hong Q; Olivo MS; Itri LM; Rugo HS;
N Engl J Med; 2021 Apr; 384(16):1529-1541. PubMed ID: 33882206
[TBL] [Abstract][Full Text] [Related]
8. Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities.
Spring LM; Nakajima E; Hutchinson J; Viscosi E; Blouin G; Weekes C; Rugo H; Moy B; Bardia A
Oncologist; 2021 Oct; 26(10):827-834. PubMed ID: 34176192
[TBL] [Abstract][Full Text] [Related]
9. Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer.
Weiss J; Glode A; Messersmith WA; Diamond J
Expert Rev Anticancer Ther; 2019 Aug; 19(8):673-679. PubMed ID: 31398063
[No Abstract] [Full Text] [Related]
10. [New drug approval: Sacituzumab govitecan in third line in advanced or metastatic triple-negative breast cancer].
Kabirian R; Da Silva A
Bull Cancer; 2022 Mar; 109(3):249-250. PubMed ID: 35094841
[No Abstract] [Full Text] [Related]
11. Sacituzumab govitecan-hziy for triple-negative breast cancer.
Stirrups R
Lancet Oncol; 2019 Apr; 20(4):e194. PubMed ID: 30827748
[No Abstract] [Full Text] [Related]
12. [Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates].
Dalenc F; Sarradin V; Nicolaï V; Franchet C; Ung M
Bull Cancer; 2021 Jan; 108(1):67-79. PubMed ID: 33422340
[TBL] [Abstract][Full Text] [Related]
13. FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer.
Wahby S; Fashoyin-Aje L; Osgood CL; Cheng J; Fiero MH; Zhang L; Tang S; Hamed SS; Song P; Charlab R; Dorff SE; Ricks TK; Barnett-Ringgold K; Dinin J; Goldberg KB; Theoret MR; Pazdur R; Amiri-Kordestani L; Beaver JA
Clin Cancer Res; 2021 Apr; 27(7):1850-1854. PubMed ID: 33168656
[TBL] [Abstract][Full Text] [Related]
14. A closer look at sacituzumab govitecan-hziy.
Bardia A
Clin Adv Hematol Oncol; 2020 Nov; 18(11):715-717. PubMed ID: 33406063
[No Abstract] [Full Text] [Related]
15. New data for sacituzumab govitecan-hziy in the treatment of metastatic triple-negative breast cancer.
Bardia A
Clin Adv Hematol Oncol; 2021 Nov; 19(11):723-725. PubMed ID: 34807017
[No Abstract] [Full Text] [Related]
16. Role of sacituzumab govitecan in solid tumors.
Veeraballi S; Khawar Z; Aslam HM; Muzaffar M
J Oncol Pharm Pract; 2022 Oct; 28(7):1617-1623. PubMed ID: 35404158
[TBL] [Abstract][Full Text] [Related]
17. Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates.
Nagayama A; Vidula N; Bardia A
Oncology (Williston Park); 2021 May; 35(5):249-254. PubMed ID: 33983696
[TBL] [Abstract][Full Text] [Related]
18. Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.
Furlanetto J; Marmé F; Loibl S
Future Oncol; 2022 Sep; 18(28):3199-3215. PubMed ID: 36069628
[TBL] [Abstract][Full Text] [Related]
19. Triple negative breast cancer: any closer to cracking the code?
Peddi PF
Curr Opin Obstet Gynecol; 2022 Feb; 34(1):52-55. PubMed ID: 34967815
[TBL] [Abstract][Full Text] [Related]
20. A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer.
Bardia A; Hurvitz SA; Rugo HS; Brufsky A; Cortes J; Loibl S; Piccart M; Cowden J; Spears P; Carey LA
Future Oncol; 2021 Oct; 17(30):3911-3924. PubMed ID: 34467774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
